Glenmark Pharmaceuticals’ subsidiary--Glenmark Therapeutics Inc., USA has launched Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC); compare to the active ingredient in MiraLAX Powder for Solution, 17 grams of Bayer HealthCare LLC. Glenmark’s Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC) is only marketed for the indications listed in Glenmark’s approved drug facts label.
According to Nielsen syndicated data for the latest 52 weeks’ period ending February 22, 2025, the MiraLAX Powder for Solution, 17 grams (OTC) market achieved annual sales of approximately $555.7 million.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: